Rockville-based Synthetic Biologics Inc. received fast-track status from the Food and Drug Administration for a drug candidate that might prevent one of the most common health care-associated infections in the U.S. Clostridium difficile, often referred to as C. diff, sickens more than 450,000 patients in the U.S. every year and causes $1.5 billion in additional health care costs annually. The drug candidate SYN-004 is an oral enzyme designed to protect the gut microbiome against C. diff and the…
from http://www.bizjournals.com/baltimore/news/2017/05/12/this-rockville-company-just-won-breakthrough.html?ana=RSS%26s=article_search
via http://baltimorecheckbook.tumblr.com/post/160581693737
No comments:
Post a Comment